Source:http://linkedlifedata.com/resource/pubmed/id/14678032
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-12-17
|
| pubmed:abstractText |
Treatment with a single injection of anti-CD40L (CD154) monoclonal antibody (mAb) and fully mismatched allogeneic bone marrow transplant (BMT) allows rapid tolerization of CD4+ T cells to the donor. The addition of in vivo CD8 T-cell depletion leads to permanent mixed hematopoietic chimerism and tolerance. We now describe two approaches that obviate the requirement for CD8 T-cell depletion by rapidly tolerizing recipient CD8 T cells in addition to CD4 cells. Administration of donor-specific transfusion (DST) to mice receiving 3 Gy total body irradiation (TBI), BMT and anti-CD40L mAb on day 0 uniformly led to permanent mixed chimerism and tolerance, compared with only 40% of mice receiving similar treatment without DST. In the absence of DST, moving the timing of 3 Gy TBI to day -1 or day -2 instead of day 0 led to rapid (by 2 weeks) induction of CD8+ cell tolerance, and also permitted uniform achievement of permanent mixed chimerism and donor-specific tolerance in recipients of anti-CD40L and BMT on day 0. These nontoxic regimens overcome CD8+ and CD4+ T-cell-mediated alloresistance without requiring host T-cell depletion, permitting the induction of permanent mixed chimerism and tolerance.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1600-6135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
31-40
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:14678032-Animals,
pubmed-meshheading:14678032-Antibodies, Monoclonal,
pubmed-meshheading:14678032-Bone Marrow Transplantation,
pubmed-meshheading:14678032-CD4-Positive T-Lymphocytes,
pubmed-meshheading:14678032-CD40 Ligand,
pubmed-meshheading:14678032-CD8-Positive T-Lymphocytes,
pubmed-meshheading:14678032-Cell Lineage,
pubmed-meshheading:14678032-Combined Modality Therapy,
pubmed-meshheading:14678032-Female,
pubmed-meshheading:14678032-Flow Cytometry,
pubmed-meshheading:14678032-Lymphocytes,
pubmed-meshheading:14678032-Mice,
pubmed-meshheading:14678032-Mice, Inbred C57BL,
pubmed-meshheading:14678032-Skin,
pubmed-meshheading:14678032-Spleen,
pubmed-meshheading:14678032-T-Lymphocytes,
pubmed-meshheading:14678032-Time Factors,
pubmed-meshheading:14678032-Transplantation, Homologous,
pubmed-meshheading:14678032-Whole-Body Irradiation
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L.
|
| pubmed:affiliation |
Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA , USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|